Todd M. Arthur, MD
Pediatric Epileptologist
is interested in mild traumatic brain injuries (concussions) in children. It is hoped by approaching the diagnosis and treatment of concussion in a systematic manner that we can improve the quality of life and outcomes of children following mild traumatic brain injuries.
513-636-4222
Todd M. Arthur, MD
Pediatric Epileptologist
Academic Information
Assistant Professor, UC Department of Pediatrics
Show All
Specialties
Neurophysiology in the ICU; epilepsy
Education and Training
MD: University of Cincinnati College of Medicine, Cincinnati, OH. Residency: Pediatrics, West Virginia University, Charleston; Pediatric Neurology, University of Washington. Fellowship: Pediatric Clinical Neurophysiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH. Certification: American Board of Pediatrics, 2002.
|
James (Jim) J. Collins, MD, PhD
Assistant Professor of Child Neurology
focuses on improving outcomes in neuromuscular disorders. He is particularly interested in individuals affected with congenital muscular dystrophy. Research focuses on the development of common data elements, outcome measures and biomarker discovery in preparation for future clinical therapeutic trials.
513-636-4222
james.collins@cchmc.org
James (Jim) J. Collins, MD, PhD
Assistant Professor of Child Neurology
Academic Information
Assistant Professor, UC Department of Pediatrics
Show All
Specialties
Congenital muscular dystrophies; merosin-deficient congenital muscular dystrophy
Biography
James Collins MD, PhD obtained specialty training in Neuromuscular disorders at the Institute of Human Genetics, Centre for Life, University of Newcastle, Newcastle, UK, in the last months of his residency training. He was then appointed Assistant Professor at Cincinnati Children’s Hospital Medical Center where he follows patients in general Neurology and in the Comprehensive Neuromuscular Center.
Education and Training
PhD: Kent State University, Kent, OH 2000.
MD: University of Cincinnati, Cincinnati, OH 2004.
Residency: Pediatric Neurology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 2009.
Certification: Child Neurology, 2009.
Publications
View PubMed Publications
Collins J and Bönneman CG. Congenital Muscular Dystrophies: Toward Molecular Therapeutic Intervention. Current Neurology and Neuroscience Reports. 2010 Mar;10(2):83-91. Collins J, Tang LY, Dimmock D, Morehart P, Bove K, Wong LJC, Wong B. Progressive myofiber changes of a childhood mitochondrial DNA depletion syndrome with a novel Thymidine Kinase 2 gene mutation. Neuromuscul Disord. 2009;19:784-787.
|
David Neal Franz, MD
Director, Tuberous Sclerosis Clinic
focuses on using a combination of clinical investigation, basic science research and innovative social programs to improve clinical care for patients with tuberous sclerosis complex (TSC). He and his team are active in human clinical trials with mTOR inhibitors to treat subependymal giant cell astrocytoma (SEGA), epilepsy and cognitive disabilities that occur in patients with TSC. In the laboratory, he is focused on understanding the mechanisms through which mTOR dysregulation in the brain contributes to TSC disease pathogenesis and developing suitable biomarkers capable of predicting disease severity and treatment response.
513-636-4222
franz@cchmc.org
David Neal Franz, MD
Director, Tuberous Sclerosis Clinic
Associate Director of Clinical Affairs, Division of Neurology
Academic Information
Professor, UC Department of Pediatrics
Show All
Specialties
Tuberous sclerosis (adults and children); neuropharmacology; neurocutaneous disorders; general pediatric neurology
Biography
David Neal Franz, MD, was born and raised in Dayton, Ohio. He received his undergraduate degree in History and Literature from Earlham College in Richmond, Indiana. After completing his training, he served as Assistant Professor of Neurology and Pediatrics at Wright State University before returning to Cincinnati Children's Hospital Medical Center. He established the Cincinnati Tuberous Sclerosis Clinic in 1993, to assist in the medical care of patients who have or are suspected of having tuberous sclerosis. The purpose of the clinic is not to replace care from the child's pediatrician or family physician, but to assist the primary care physician in dealing with those aspects unique to tuberous sclerosis that affect the child's health or development. The basis of the clinic is the realization that people with tuberous sclerosis are different from other individuals who have epilepsy, learning disabilities, behavior problems, etc. For too long, the unique problems found in this disease have been lumped together with similar disorders, despite the fact that research has shown that disorders of the brain, heart, kidney, and other organs in tuberous sclerosis are quite different.
Education and Training
MD: Ohio State University College of Medicine, Columbus, OH, 1985.
Residency: Wright State University Affiliated Hospitals, Dayton, OH.
Fellowship: Children's Hospital Medical Center, Cincinnati, OH.
Certification: Pediatrics, 1990; Neurology with special competence in child neurology, 1992.
Publications
View PubMed Publications
Franz DN, Bissler JJ, McCormack FX. Tuberous sclerosis complex: neurological, renal and pulmonary manifestations. Neuropediatrics. 2010 Oct;41(5):199-208. Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010 Nov 4;363(19):1801-11. Young LR, Vandyke R, Gulleman PM, Inoue Y, Brown KK, Schmidt LS, Linehan WM, Hajjar F, Kinder BW, Trapnell BC, Bissler JJ, Franz DN, McCormack FX. Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest. 2010 Sep;138(3):674-81. Young LR, Franz DN, Nagarkatte P, Fletcher CD, Wikenheiser-Brokamp KA, Galsky MD, Corbridge TC, Lam AP, Gelfand MJ, McCormack FX. Utility of [18F]2-fluoro-2-deoxyglucose-PET in sporadic and tuberous sclerosis-associated lymphangioleiomyomatosis. Chest. 2009 Sep;136(3):926-33. Schmithorst VJ, Altes TA, Young LR, Franz DN, Bissler JJ, McCormack FX, Dardzinski BJ, Brody AS. Automated algorithm for quantifying the extent of cystic change on volumetric chest CT: initial results in Lymphangioleiomyomatosis. AJR Am J Roentgenol. 2009 Apr;192(4):1037-44. Krueger DA, Franz DN. Current management of tuberous sclerosis complex. Paediatr Drugs. 2008;10(5):299-313. Review. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, Salisbury S, Franz DN. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008 Jan 10;358(2):140-51. Levine NB, Collins J, Franz DN, Crone KR. Gradual formation of an operative corridor by balloon dilation for resection of subependymal giant cell astrocytomas in children with tuberous sclerosis: specialized minimal access technique of balloon dilation. Minim Invasive Neurosurg. 2006 Oct;49(5):317-20. Collins JJ, Tudor C, Leonard JM, Chuck G, Franz DN. Levetiracetam as adjunctive antiepileptic therapy for patients with tuberous sclerosis complex: a retrospective open-label trial. J Child Neurol. 2006 Jan;21(1):53-7. Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G, Dinopoulos A, Thomas G, Crone KR. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol. 2006 Mar;59(3):490-8.
|
Donald L. Gilbert, MD, MS
Director, Movement Disorder Clinic and Tourette's Syndrome Clinic
is interested in motor control in children with Tourette syndrome, attention deficit hyperactivity disorder, and other conditions that affect movement. To do this, the team’s laboratory uses transcranial magnetic stimulation (TMS) to measure signals in the motor control areas of the brain and measures motor coordination in the hands. The team is also using the TMS magnet to try to improve how the brain controls speech in adults who have suffered strokes; they hope to bring this type of treatment to children in the future. The team also does trials of new medications for Tourette syndrome. Visit the Gilbert/Wu Lab.
513-636-4222
donald.gilbert@cchmc.org
Donald L. Gilbert, MD, MS
Director, Movement Disorder Clinic and Tourette's Syndrome Clinic
Academic Information
Professor, UC Department of Pediatrics
Show All
Specialties
Clinical InterestsMovement disorders; Tourette's Syndrome; Sydenham's Chorea; kernicterus; dystonia; ataxia; clinical research; transcranial magnetic stimulation Research InterestsClinical trials in Tourette's Syndrome and associated ADHD; epidemiology of Tourette's Syndrome and PANDAS; clinical effectiveness of multi-drug treatments in Tourette's Syndrome; transcranial magnetic stimulation in Tourette's Syndrome and pediatric movement disorders; functional neurosurgery for pediatric dystonia Visit the Gilbert-Wu Lab.
Biography
Donald Gilbert, MD, earned his Bachelor of Arts at Princeton University, where he majored in philosophy. He subsequently earned his MD at the University of Michigan and spent a year at the National Institutes of Health as a Howard Hughes Medical Institute Research Scholar. Dr. Gilbert did his pediatrics and neurology training at John Hopkins in Baltimore and is board certified in neurology with special competence in child neurology. Dr. Gilbert has an MS in Clinical Research Design and Statistical Analysis from the University of Michigan. At Cincinnati Children's, Dr. Gilbert directs the Movement Disorders and Tourette's Syndrome Clinics, which specialize in evaluation and pharmacologic treatment of tics, chorea, tremor, dystonia, stereotypies, ataxia, and other movement disorders. Dr. Gilbert directs or participates in a number of single and multi-center studies into causes and treatments of Tourette's Syndrome. Dr. Gilbert directs the Transcranial Magnetic Stimulation Laboratory at CCHMC.
Education and Training
BA: Princeton University, Princeton, NJ, 1987.
MD: University of Michigan School of Medicine, Ann Arbor, MI, 1993.
MS: University of Michigan, Ann Arbor, MI, 2003.
Residency: Johns Hopkins School of Medicine, Baltimore, MD, 1995.
Fellowship: Johns Hopkins School of Medicine, Baltimore, MD, 1995.
Certification: Board Certified in Neurology with Special Competence in Child Neurology, 2010. Board eligible in Pediatrics.
Appointment: Associate Professor of Pediatric Neurology.
Publications
View PubMed Publications
Ridel KR, Gilbert DL. Child neurology: past, present, and future: part 3: the future. Neurology. 2010 Oct 12;75(15):e62-4. Wu SW, Harris E, Gilbert DL. Tic suppression: the medical model. J Child Adolesc Psychopharmacol. 2010 Aug;20(4):263-76.
Dalal P, Leslie ND, Lindor NM, Gilbert DL, Espay AJ. Motor tics, stereotypies, and self-flagellation in primrose syndrome. Neurology. 2010 Jul 20;75(3):284-6. Ridel KR, Lipps TD, Gilbert DL. The prevalence of neuropsychiatric disorders in Sydenham's chorea. Pediatr Neurol. 2010 Apr;42(4):243-8. Hopkins SE, Somoza A, Gilbert DL. Rare autosomal dominant POLG1 mutation in a family with metabolic strokes, posterior column spinal degeneration, and multi-endocrine disease. J Child Neurol. 2010 Jun;25(6):752-6. Degrauw RS, Li JZ, Gilbert DL. Body mass index changes and chronic neuroleptic drug treatment for Tourette syndrome. Pediatr Neurol. 2009 Sep;41(3):183-6. Gilbert DL. Acute and chronic chorea in childhood. Semin Pediatr Neurol. 2009 Jun;16(2):71-6. Review. Wong B, Gilbert DL, Walker WL, Liao IH, Lit L, Stamova B, Jickling G, Apperson M, Sharp FR. Gene expression in blood of subjects with Duchenne muscular dystrophy. Neurogenetics. 2009 Apr;10(2):117-25. Gilbert DL, Leslie EJ, Keddache M, Leslie ND. A novel hereditary spastic paraplegia with dystonia linked to chromosome 2q24-2q31. Mov Disord. 2009 Feb 15;24(3):364-70. Gilbert DL. Drug-induced movement disorders in children. Ann N Y Acad Sci. 2008 Oct;1142:72-84. Review.
|
Tracy A. Glauser, MD
Director, Comprehensive Epilepsy Center
is the Director of the Comprehensive Epilepsy Center and co-director of the Genetic Pharmacology Service. His research has focused on improving the care of children with epilepsy through identifying the genetic and non-heritable factors that underlie the inter-individual variation in response to antiepileptic medications. Since 2003, he has directed the NIH-funded Childhood Absence Epilepsy trial, a 31-center, 446-patient double-blind randomized comparative trial of three commonly used antiepileptic medications focused on identifying the optimal initial therapy for children with childhood absence epilepsy and the pharmacokinetic, pharmacodynamic, and pharmacogenetic factors that impact the inter-individual response to antiepileptic therapy. Glauser and the Genetic Pharmacology Service (www.gps.cchmc.org) have also developed and are testing treatment selection algorithms for epilepsy and non-epilepsy medications that incorporate genetic information and drug-drug interactions.
513-636-4222
tracy.glauser@cchmc.org
Tracy A. Glauser, MD
Director, Comprehensive Epilepsy Center
Co-Director, Genetic Pharmacology Service
Academic Information
Professor, UC Department of Pediatrics
Show All
Specialties
Clinical InterestsEpilepsy; pharmacogenetics; clinical pharmacology Research InterestsClinical pharmacology; pharmacogenetics; antiepileptic clinical trials
Biography
Tracy A. Glauser, MD, is professor of Pediatrics, director of the Comprehensive Epilepsy Center and co-director of the Genetic Pharmacology Service at Cincinnati Children’s Hospital Medical Center. Dr. Glauser received his medical degree, cum laude, from Jefferson Medical College in Philadelphia, PA. He completed his residency in pediatrics at the John Hopkins Hospital in Baltimore, MD, and fellowship in child neurology at The Children’s Hospital of Philadelphia, University of Pennsylvania in Philadelphia, PA. Dr. Glauser completed a National Institute of Neurological Disorders and Stroke research fellowship in pediatric neurology and was a fellow in epilepsy and electroencephalography at St. Louis Children’s Hospital, Washington University School of Medicine in St. Louis, Missouri.
Dr. Glauser has authored and co-authored more than 130 articles and book chapters, been involved with the development of 6 evidence based guidelines about epilepsy therapy and given over 150 invited lectures throughout the world. He has been the principal investigator on multiple NIH grants. Currently, Dr. Glauser directs the NIH funded Childhood Absence Epilepsy clinical trial involving 32 pediatric centers around the United States. Dr. Glauser’s fields of expertise are pediatric neurology, pediatric epilepsy, clinical pharmacology and pharmacogenetics.
Education and Training
MD: Jefferson Medical College, Philadelphia, PA, 1985.
Residency: Johns Hopkins Hospital, Baltimore, MD.
Fellowship: St. Louis Children's Hospital, St. Louis, MO.
Certification: Pediatrics, 1990; Neurology (with special competence in child neurology), 1991.
Publications
View PubMed Publications
Modi AC, Guilfoyle SM, Morita DA, Glauser TA. Development and reliability of a correction factor for parent-reported adherence to pediatric antiepileptic drug therapy. Epilepsia. 2010 Nov 18. doi: 10.1111/j.1528-1167.2010.02789.x. Modi AC, Monahan S, Daniels D, Glauser TA. Development and validation of the Pediatric Epilepsy Medication Self-Management Questionnaire. Epilepsy Behav. 2010 May;18(1-2):94-9 Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Capparelli EV, Adamson PC; Childhood Absence Epilepsy Study Group. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med. 2010 Mar 4;362(9):790-9. Holland KD, Monahan S, Morita D, Vartzelis G, Glauser TA. Valproate in children with newly diagnosed idiopathic generalized epilepsy. Acta Neurol Scand. 2010 Mar;121(3):149-53. Pestian J, Spencer M, Matykiewicz P, Zhang K, Vinks AA, Glauser T. Personalizing Drug Selection Using Advanced Clinical Decision Support. Biomed Inform Insights. 2009 Jun 23;2:19-29. Prows CA, Nick TG, Saldaña SN, Pathak S, Liu C, Zhang K, Daniels ZS, Vinks AA, Glauser TA. Drug-metabolizing enzyme genotypes and aggressive behavior treatment response in hospitalized pediatric psychiatric patients. J Child Adolesc Psychopharmacol. 2009 Aug;19(4):385-94. Modi AC, King AS, Monahan SR, Koumoutsos JE, Morita DA, Glauser TA. Even a single seizure negatively impacts pediatric health-related quality of life. Epilepsia. 2009 Sep;50(9):2110-6. Daniels ZS, Nick TG, Liu C, Cassedy A, Glauser TA. Obesity is a common comorbidity for pediatric patients with untreated, newly diagnosed epilepsy. Neurology. 2009 Sep 1;73(9):658-64. Glauser TA, Sankar R; Co-chairs of the Leadership in Epilepsy, Advocacy, and Development Faculty. Core elements of epilepsy diagnosis and management: expert consensus from the Leadership in Epilepsy, Advocacy, and Development (LEAD) faculty. Curr Med Res Opin. 2008 Dec;24(12):3463-77. Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology. 2008 May 20;70(21):1950-8.
Grants
Sodium channel gene variation in the treatment of epilepsy. Collaborator. Apr 2009 - Mar 2014. #R01NS062756.
The epilepsy phenome/ genome project (EPGP). Pharmacogenetics Core/Site Principal Investigator. May 2007- Apr 2012. #R01NS053998.
|
Barbara E. Hallinan, MD, PhD
Pediatric Neurologist
focuses on investigating the neurochemical mechanisms responsible for the onset of epilepsy in infants, especially infantile spasms. Early diagnosis and treatment of epilepsy in this age group has the potential to improve developmental outcome. It is hoped that a better understanding of the pathogenesis of epilepsy in infants will shift the treatment paradigm from managing the clinical convulsions to correcting the underlying neurochemical pathology.
513-636-4222
Barbara E. Hallinan, MD, PhD
Pediatric Neurologist
Academic Information
Assistant Professor, UC Department of Pediatrics
Phone: 513-636-4222
Fax: 513-636-1888
Show All
Specialties
Education and Training
PhD: Florida State University, Tallahassee, FL, 1989.
MD: University of Cincinnati College of Medicine, Cincinnati, OH, 2001.
Residency: Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Certification: Pediatrics, 2007; Neurology with Special Qualification in Child Neurology, 2007.
Publications
View PubMed Publications
Dent CL, Spaeth JP, Jones BV, Schwartz SM, Glauser TA, Hallinan B, Pearl JM, Khoury PR, Kurth CD. Brain magnetic resonance imaging abnormalities after the Norwood procedure using regional cerebral perfusion. J Thorac Cardiovasc Surg. 2006 Jan;131(1):190-7. Retraction in: J Thorac Cardiovasc Surg. 2006 Jun;131(6):1226. Dent CL, Spaeth JP, Jones BV, Schwartz SM, Glauser TA, Hallinan B, Pearl JM, Khoury PR, Kurth CD. Brain magnetic resonance imaging abnormalities after the Norwood procedure using regional cerebral perfusion. J Thorac Cardiovasc Surg. 2005 Dec;130(6):1523-30.
|
Andrew D. Hershey, MD, PhD, FAHS
Associate Director of Research, Division of Neurology
is interested in the characterization, molecular pathophysiology and neurophysiological, and outcome of pediatric and adolescent headache. This has extended from characterization of headache and changes across the ages and for specific headache and migraine types. The pathophysiology has included gene expression patterns of risk and response, mitochondrial cofactors and neurophysiological responses.
513-636-4222
andrew.hershey@cchmc.org
Andrew D. Hershey, MD, PhD, FAHS
Associate Director of Research, Division of Neurology
Academic Information
Professor, UC Department of Pediatrics
Show All
Specialties
Clinical InterestsHeadaches; migraines; neurogenetics; neurometabolic disorders Research InterestsEpidemiology; diagnostic criteria; treatment evaluation; outcome responses; quality of life issues; pharmaceutical trials; and neurogenetics of childhood headaches
Biography
Andrew Hershey, MD, PhD, received his undergraduate degree at the University of Iowa, Iowa City, Iowa. He earned an honors degree in Biochemistry; his research involved the enzyme kinetic properties of alcohol dehydrogenase in yeast. After undergraduate school, Dr. Hershey attended the MD/PhD program at Washington University, St. Louis, Missouri. His Ph.D. research thesis was entitled: "The Rat Substance P Receptor: cDNA and Genomic Cloning, Functional Expression, mRNA Distribution, and Mutational Analysis of Desensitization Responses." After earning his MD and PhD, Dr. Hershey was an intern and resident in pediatrics at St. Louis Children's Hospital, St. Louis, MO. He then was an adult neurology resident at Barnes-Jewish Hospital, St. Louis, MO, followed by his child neurology fellowship at St. Louis Children's Hospital, St. Louis, MO. After his fellowship, Dr. Hershey joined the faculty at Cincinnati Children's Hospital Medical Center, Ohio, where he is director of the Headache Center. Dr. Hershey's research interests currently include the improved diagnosis and treatment of childhood headache disorders, characterization of outcome responses, studies in new pharmacological and non-pharmacological treatment regimes, and the neurogenetics of migraines.
Education and Training
BS: University of Iowa, Iowa City, IA, 1985.
MD: Washington University, St. Louis, MO, 1992.
PhD: Washington University, St. Louis, MO, 1992.
Residency: St. Louis Childrens Hospital, St. Louis, MO, 1993-1994; Barnes-Jewish Hospital, St. Louis, MO,1994-1995.
Fellowship: St. Louis Childrens Hospital, St. Louis, MO, 1995-1997.
Certification: Neurology with special competence in child neurology, 1998, recertified 2008; Headache Medicine, 2006.
Publications
View PubMed Publications
Hershey AD, Burdine D, Kabbouche MA, Powers SW. Genomic expression patterns in medication overuse headaches. Cephalalgia. 2011 Jan;31(2):161-71. O'Brien HL, Kabbouche MA, Hershey AD. Treatment of acute migraine in the pediatric population. Curr Treat Options Neurol. 2010 May;12(3):178-85. Hershey AD, Kabbouche MA, Powers SW. Treatment of pediatric and adolescent migraine. Pediatr Ann. 2010 Jul;39(7):416-23. doi: 10.3928/00904481-20100623-06. Review. Wang X, Xiang J, Wang Y, Pardos M, Meng L, Huo X, Korostenskaja M, Powers SW, Kabbouche MA, Hershey AD. Identification of abnormal neuromagnetic signatures in the motor cortex of adolescent migraine. Headache. 2010 Jun;50(6):1005-16. Hershey AD. Recent developments in pediatric headache. Curr Opin Neurol. 2010 Jun;23(3):249-53. Review. Hershey AD. Current approaches to the diagnosis and management of paediatric migraine. Lancet Neurol. 2010 Feb;9(2):190-204. Review. Slater S, Crawford MJ, Kabbouche MA, LeCates SL, Cherney S, Vaughan P, Segers A, Manning P, Burdine D, Powers SS, Hershey AD. Effects of gender and age on paediatric headache. Cephalalgia. 2009 Sep;29(9):969-73. Khatri R, Hershey AD, Wong B. Prochlorperazine -- treatment for acute confusional migraine. Headache. 2009 Mar;49(3):477-80.
Hershey AD. Menstrual migraine: how early can it start? Headache. 2009 Mar;49(3):348-9. Crawford MJ, Lehman L, Slater S, Kabbouche MA, LeCates SL, Segers A, Manning P, Powers SW, Hershey AD.
Menstrual migraine in adolescents. Headache. 2009 Mar;49(3):341-7.
|
Katherine D. Holland-Bouley, MD, PhD
Pediatric Epileptologist
focuses on understanding the reasons medications fail to control seizures in certain people with epilepsy. This work includes development of clear definitions of drug response, analysis of genetic factors that predict treatment response and analyzing the neurophysiological differences between treatment responsive and treatment resistant epilepsy. The goal of this work is to predict treatment response so that care can be more individualized.
katherine.holland@cchmc.org
Katherine D. Holland-Bouley, MD, PhD
Pediatric Epileptologist
Academic Information
Assistant Professor, UC Department of Pediatrics
Show All
Specialties
Mechanisms of epileptogenesis
Education and Training
MD: Washington University, St Louis MO, 1991.
PhD (pharmacology): Washington University, St Louis MO, 1991.
Internship: Children's Hospital, Boston MA.
Residency: St Louis Children's Hospital, St Louis, MO.
Certification: Neurology with added qualification in pediatric neurology, 2000.
Publications
View PubMed Publications
Standridge SM, Holland KD, Horn PS. Cardiac arrhythmias and ictal events within an epilepsy monitoring unit. Pediatr Neurol. 2010 Mar;42(3):201-5.
Holland KD, Monahan S, Morita D, Vartzelis G, Glauser TA. Valproate in children with newly diagnosed idiopathic generalized epilepsy. Acta Neurol Scand. 2010 Mar;121(3):149-53.
Holland KD, Kearney JA, Glauser TA, Buck G, Keddache M, Blankston JR, Glaaser IW, Kass RS, Meisler MH. Mutation of sodium channel SCN3A in a patient with cryptogenic pediatric partial epilepsy. Neurosci Lett. 2008 Mar 5;433(1):65-70.
Holland KD, Glauser TA. Response to carbamazepine in children with newly diagnosed partial onset epilepsy. Neurology. 2007 Aug 7;69(6):596-9.
Holland KD, Fleming MT, Cheek S, Moran JL, Beier DR, Meisler MH. De novo exon duplication in a new allele of mouse Glra1 (spasmodic). Genetics. 2006 Dec;174(4):2245-7.
|
Sejal V. Jain, MD
Director, Epilepsy-Sleep Clinical Program
is interested in the field of sleep and epilepsy and their interactions. Working on identifying prevalence of sleep disorder, screening methods and ideal treatments for sleep disorders in patients with epilepsy. The goal is also to identify the impact of treatment of sleep disorders on seizure control in these patients.
513-636-4222
sejal.jain@cchmc.org
Sejal V. Jain, MD
Director, Epilepsy-Sleep Clinical Program
Director, Epilepsy/Clinical Neurophysiology Fellowship Program
Pediatric Epileptologist
Academic Information
Assistant Professor, UC Department of Pediatrics
Show All
Specialties
Clinical InterestsMedical and surgical management of epilepsy; sleep disorders Research InterestsSleep disorders in children with epilepsy; clinical drug trials
Biography
Dr. Jain is a clinical researcher who is trained in pediatric epilepsy and sleep medicine. Her clinical research is focused on sleep disorders in children with epilepsy. The core of her research is to identify the best treatment options for sleep disorders in children with epilepsy and evaluate the impact on seizure control. Dr. Jain is also interested in antiepileptic drug trials. Dr. Jain developed and is currently directing the Epilepsy-Sleep Clinical Program. She also directs the Epilepsy/Clinical Neurophysiology Fellowship Program. She is ranked among America’s top physicians (Consumer Research Council of America, 2009-2012).
Education and Training
MD: Gujarat University, India.
Residency: Nassau University Medical Center, NY.
Fellowships: Clinical Neurophysiology and Pediatric Neurology, Virginia Commonwealth University, Richmond, Virginia; Sleep Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Certifications: Neurology (Child Neurology); Clinical Neurophysiology, Sleep Medicine.
Publications
View PubMed Publications
Jain SV, Simakajornboon N, Glauser, TA. Provider practices impact adequate diagnosis of sleep disorders in children with epilepsy. J Child Neurol. 2013 May;28(5):589-95. Natarajan, N, Jain SV, Chaudhry H, Hallinan BE, Simakajornboon N. Narcolepsy-cataplexy: is streptococcal infection a trigger? J Clin Sleep Med. 2013 Mar 15;9(3):269-70. Jain SV, Horn PS, Simakajornboon N, Glauser, TA. Obstructive sleep apnea and primary snoring in children with epilepsy. J Child Neurol. 2013 Jan;28(1):77-82. Jain SV, Simakajornboon N, Arthur TM. Central sleep apnea: does stabilizing sleep improve it?J Child Neurol. 2012 Dec 5. [Epub ahead of print] Fujiwara H, Greiner HM, Hemasilpin N, Lee KH, Holland-Bouley K, Arthur T, Morita D, Jain SV, Mangano FT, Degrauw T, Rose DF. Ictal MEG onset source localization compared to intracranial EEG and outcome: improved epilepsy presurgical evaluation in pediatrics. Epilepsy Res. 2012 May;99(3):214-24. Jain SV, Simakajornboon S, Shapiro SM, Morton LD, Leszczyszyn DJ, Simakajornboon N. Obstructive sleep apnea in children with epilepsy: prospective pilot trial. Acta Neurol Scand. 2012 Jan;125(1):e3-6. Jain SV, Kothare SV. Should we be targeting the sleep-wake patterns of children with epilepsy? Neuropsychiatry. 2011;1(6), 517–520. Book ChaptersJain SV. Sleep Terrors and Confusional Arousals in Children and Adolescent. In Kothare SV and Ivanenko A. Prasomnia: Clinical Characteristics and Treatment. Springer (in press). Arya R, Jain SV. Sleep Walking in Children and Adolescent. In Kothare SV and Ivanenko A. Prasomnia: Clinical Characteristics and Treatment. Springer (in press). Jain SV, Morton LD. Evaluating the Child with Seizure: In Pellock JM, Dodson EW, Bourgeois BF, and Nordlii DR: Pediatric Epilepsy, Diagnosis and Treatment. New York, Demos Medical Publishing: Nov 2007.
Grants
Clinical Research Feasibility Funds (CReFF). Principle Investigator. Center for Clinical and Translational Science and Training, Cincinnati Children’s Hospital Medical Center. Apr 2010 - Jul 2013. Clinical and Translational Science Award (CTSA). Principle Investigator. The National Center for Research Resources, NIH. Jul 2010 - Jul 2013. USPHS Grant # UL1RR026314.
|
Marielle A. Kabbouche, MD
Child Neurologist
is interested in acute treatment of intractable migraine headache including emergency room evaluation and treatment as well as inpatient therapies. The goal is not only to identify intractable headache but being able to identify short-term as well as long-term outcome to these interventions in children and adolescents.
513-636-4222
marielle.kabbouche@cchmc.org
Marielle A. Kabbouche, MD
Child Neurologist
Academic Information
Associate Professor, UC Department of Pediatrics
Show All
Specialties
Clinical InterestsHeadaches; migraines; acute and inpatient treatment of intractable headache Research InterestsHeadache; outcome studies; health improvement; clinical effectiveness
Biography
Marielle Kabbouche, MD, received her training in Child Neurology at Vanderbilt University school of medicine. She moved to Cincinnati for a specialty training in pediatric headache medicine . The position was the first for a pediatric neurologist.
After her headache training she stayed at Cincinnati Children's as faculty and active member of the center with involvement in all academic as well as clinical and teaching aspect of pediatric headache. Since that time she has been proud to be part of the maturing center that gradually developed to be the largest and most academically productive pediatric headache program in the United States and worldwide. She has been a co- PI on multiple NIH grants since 2002 and have been involved in multiple pharmaceutical and clinical studies in pediatric and adolescent migraine.
Her carrier has been focused on acute treatment of intractable Migraine in Children in emergency room as well as inpatient settings.
As the Director of the inpatient headache unit, Dr. Kabbouche was actively involved in setting an acute headache infusion center as well as an inpatient headache unit at Cincinnati Children’s Hospital Medical Center. The Headache acute care unit has been very productive in the last few years and seeing about 200-300 patients/year during peak seasons. The inpatient unit will open in July of 2011 bringing specialty care to the headache patients with a team of 6 providers , fellows , residents and nurses. This approach to intractable headache care will have a great impact on patient’s outcome.
Dr. Kabbouche has over 25 publications, and a track record of numerous peer-reviewed papers, reviews, and abstracts in the field of headache medicine, book chapters as well as being an editor of a pediatric headache book.
Education and Training
MD: Saint Joseph University, Faculty of Medicine, Beirut, Lebanon.
Residency: Vanderbilt University Medical Center, Nashville, TN.
Fellowship: Cincinnati Children's Hospital, Cincinnati, OH.
Publications
View PubMed Publications
Hershey AD, Kabbouche MA, Powers SW. Treatment of pediatric and adolescent migraine. Pediatr Ann. 2010 Jul;39(7):416-23. Kabbouche MA, Cleves C. Evaluation and management of children and adolescents presenting with an acute setting. Semin Pediatr Neurol. 2010 Jun;17(2):105-8. Kabbouche MA, Powers SW, Segers A, LeCates S, Manning P, Biederman S, Vaughan P, Burdine D, Hershey AD. Inpatient treatment of status migraine with dihydroergotamine in children and adolescents. Headache. 2009 Jan;49(1):106-9. Kabbouche MA, Gilman DK. Management of migraine in adolescents. Neuropsychiatr Dis Treat. 2008 Jun;4(3):535-48.
Kabbouche MA, Linder SL. Management of migraine in children and adolescents in the emergency department and inpatient setting. Curr Pain Headache Rep. 2005 Oct;9(5):363-7.
Kabbouche MA, Linder SL. Acute treatment of pediatric headache in the emergency department and inpatient settings. Pediatr Ann. 2005 Jun;34(6):466-71.
Kabbouche MA, Powers SW, Vockell ALB, LeCates SL, Ellinor PL, Segers A, Manning P, Hershey AD. Outcome of a multidisciplinary approach of pediatric migraine at 1, 2, and 5 years. Headache. 2005;45:1298-1303. Book ChaptersKabbouche MA. Migraine variants. In Andrew Hershey, Scott Powers, Paul Winners and Marielle Kabbouche (Eds.) Pediatric Headache in Clinical Practice. Wiley Blackwell, 2009. Kabbouche MA. Other primary headaches. In Andrew Hershey, Scott Powers, Paul Winners and Marielle Kabbouche (Eds.) Pediatric Headache in Clinical Practice. Wiley Blackwell, 2009.
Kabbouche MA. Emergent therapy for children and adolescent. In Andrew Hershey, Scott Powers, Paul Winners and Marielle Kabbouche (Eds.) Pediatric Headache in Clinical Practice. Wiley Blackwell, 2009.
Grants
Acute treatment of headaches in children and adolescents. Co-Principal Investigator. American Headache Society. 2007 - 2012. Drug & Non-Drug Treatment of Pediatric Chronic Headache. Co-Investigator. National Institute of Neurological Disorders and Stroke. 2006 - 2011. #R01 NS050536-01A1.
|
Darren S. Kadis, PhD
studies brain-behavior relationships using modern neuroimaging techniques (i.e., MRI, MEG, etc.). His research is directed at understanding the typical organization of the brain, the role of early experience on brain structure and functional representation, and the vulnerability and plasticity of the brain in the context of early neurological insult.
513-636-2577
darren.kadis@cchmc.org
Darren S. Kadis, PhD
Academic Information
Assistant Professor, UC Department of Pediatrics
Show All
Specialties
Neuroimaging; epilepsy; language
Biography
Dr. Kadis received his PhD through the Department of Psychology at the University of Toronto, with a distinction in Neuroscience and training in Clinical Neuropsychology. He conducted his graduate and post-doctoral research at the Hospital for Sick Children in Toronto, gaining experience with invasive (i.e., intracarotid sodium amobarbital procedure, electrocortical stimulation mapping) and newer noninvasive (e.g., fMRI, MEG) brain mapping procedures. His research is directed at understanding the typical organization of the brain, the role of early experience on brain structure and functional representation, and the vulnerability and plasticity of the brain in the context of early neurological insult. Currently, Dr. Kadis uses MEG in concert with structural neuroimaging and neuropsychological procedures to study speech and language representation and plasticity in the brains of children.
Education and Training
PhD: University of Toronto, ON, Canada, 2010.
Publications
View PubMed Publications
Elliott IM, Kadis DS, Lach LM, Olds J, McCleary L, Whiting S, Snyder T, Smith ML. Quality of life in young adults who underwent respective surgery for epilepsy in childhood. Epilepsia. 2012;53(9):1577-1586. Kadis DS, Pang EW, Mills T, Taylor MJ, McAndrews MP, Smith ML. Characterizing the normal developmental trajectory of expressive language lateralization using magnetoencephalography. Journal of the International Neuropsychological Society. 2011;17(5):896-904. Pang EW, Wang F, Malone M, Kadis DS, Donner EJ. Localization of Broca’s area using verb generation tasks in MEG: Validation against fMRI. Neuroscience Letters. 2011;490:215-219. Smith ML, Kelly K, Kadis DS, Elliott I, Olds J, Whiting S, Snyder T. Self-reported symptoms of psychological well-being in young adults who underwent resective epilepsy surgery in childhood. Epilepsia. 2011:52(5):891-899. Kadis DS, Kerr EN, Rutka JT, Snead III OC, Weiss SK, Smith ML. Pathology type does not predict language lateralization in children with medically intractable epilepsy. Epilepsia. 2009;50(6):1498-1504. Kadis DS, Smith ML, Mills T, Pang EW. MEG localization of expressive language cortex in healthy children: Application to paediatric clinical populations. Down Syndrome Quarterly. 2008;10(2):5-12. Elliott IM, Lach L, Kadis DS, Smith ML. Psychosocial outcomes in children two years after epilepsy surgery: Has anything changed? Epilepsia. 2008;49(4):634-641. Kadis DS, Iida K, Kerr EN, Logan WJ, McAndrews MP, Ochi A, Otsubo H, Rutka JT, Snead III OC, Weiss SK, Smith ML. Intrahemispheric reorganization of language in children with medically intractable epilepsy of the left hemisphere. Journal of the International Neurological Society. 2007;13:505-516. Kadis DS, Stollstorff M, Elliott I, Lach L, Smith ML. Cognitive and psychological predictors of everyday memory in children with intractable epilepsy. Epilepsy and Behavior. 2004;5:37-43. Kadis DS. Shock treatment for suicidal, depressed, psychotic and schizophrenic patients. In G. Allen & Science 2000 Collective (Eds.), Communicating science – a collection by new writers (2nd ed.). Toronto: Life Rattle Press. 2004.
|
Darcy A. Krueger, MD, PhD
uses a combination of clinical investigation, basic science research and innovative social programs to improve clinical care for patients with tuberous sclerosis complex (TSC). We are active in human clinical trials with mTOR inhibitors to treat subependymal giant cell astrocytoma (SEGA), epilepsy and cognitive disabilities that occur in patients with TSC. In the laboratory, we are focused on understanding the mechanisms through which mTOR dysregulation in the brain contributes to TSC disease pathogenesis and developing suitable biomarkers capable of predicting disease severity and treatment response.
513-636-4222
krueger_darcy@cchmc.org
Darcy A. Krueger, MD, PhD
Academic Information
Assistant Professor, UC Department of Pediatrics
Show All
Specialties
Clinical InterestsTuberous sclerosis; general neurology Research InterestsTuberous sclerosis; clinical use of mTOR inhibitors; role of mTOR pathway in neurological disease
Education and Training
MD: Saint Louis University School of Medicine, St. Louis, Missouri, 1995-1997; 2000-2002.
PhD: Saint Louis University Graduate School Biochemistry and Molecular Biology, St. Louis, Missouri, 1997-2000.
Publications
View PubMed Publications
Greiner H, Leach JL, Lee KH, Krueger DA. Anti-NMDA receptor encephalitis presenting with imaging findings and clinical features mimicking Rasmussen syndrome. Seizure. 2011 Apr;20(3):266-70.
Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010 Nov 4;363(19):1801-11. Krueger DA, Franz DN. Current management of tuberous sclerosis complex. Paediatr Drugs. 2008;10(5):299-313.
|
Michael V. Miles, PharmD
Director, Neuropharmacology Laboratory
focuses on development and validation of novel laboratory tests and biomarkers for monitoring mitochondrial function and oxidative stress; promoting collaborative research involving mitochondrial abnormalities associated with aging, obesity, neuromuscular diseases, epilepsy, sleep apnea and nutritional deficiencies; and evaluating the safety and efficacy of new antioxidant formulations, such as coenzyme Q and vitamin E.
513-636-7871
michael.miles@cchmc.org
Michael V. Miles, PharmD
Director, Neuropharmacology Laboratory
Academic Information
Professor, UC Department of Pediatrics
Show All
Specialties
Pediatric pharmacology; laboratory tests and biomarkers for monitoring mitochondrial function and oxidative stress; mitochondrial abnormalities associated with aging, obesity, sleep apnea, epilepsy and nutritional deficiencies; safety and efficacy of treatment with antioxidants, such as coenzyme Q and vitamin E.
Biography
Michael V. Miles, PharmD, has been a member of the Division of Pediatric Neurology for over 5 years. He is an experienced clinician and researcher, who has studied the pharmacokinetics and pharmacodynamics of drugs in pediatric populations for much of his career. He has dedicated his clinical and research efforts to improving the efficacy and safety of drug therapy for infants and children. His research is currently focused on the development of new biomarkers and therapeutic agents for patients with mitochondrial diseases.
Education and Training
PharmD: University of Texas at Austin, Austin, Texas, 1979.
Specialty Residency: Pediatric Clinical Pharmacy, University of Texas at Austin, Austin, Texas.
Certification: Pharmacy, 1976.
Publications
View PubMed Publications
Miles MV, Putnam PE, Miles L, Tang PH, DeGrauw AJ, Wong BL, Horn PS, Foote HL, Rothenberg ME. Acquired coenzyme Q10 deficiency in children with recurrent food intolerance and allergies. Mitochondrion. 2011 Jan;11(1):127-35. Kohli R, Kirby M, Xanthakos SA, Softic S, Feldstein AE, Saxena V, Tang PH, Miles L, Miles MV, Balistreri WF, Woods SC, Seeley RJ. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology. 2010 Sep;52(3):934-44. Miles MV, Tang PH, Miles L, Steele PE, Moye MJ, Horn PS. Validation and application of an HPLC-EC method for analysis of coenzyme Q10 in blood platelets. Biomed Chromatogr. 2008 Dec;22(12):1403-8. Miles MV, Miles L, Tang PH, Horn PS, Steele PE, DeGrauw AJ, Wong BL, Bove KE. Systematic evaluation of muscle coenzyme Q10 content in children with mitochondrial respiratory chain enzyme deficiencies. Mitochondrion. 2008 Mar;8(2):170-80. Miles MV, Patterson BJ, Chalfonte-Evans ML, Horn PS, Hickey FJ, Schapiro MB, Steele PE, Tang PH, Hotze SL. Coenzyme Q10 (ubiquinol-10) supplementation improves oxidative imbalance in children with trisomy 21. Pediatr Neurol. 2007 Dec;37(6):398-403. Miles MV. The uptake and distribution of coenzyme Q10. Mitochondrion. 2007 Jun;7 Suppl:S72-7. Tang PH, Miles MV, Steele P, Davidson BS, Geraghty SR, Morrow AL. Determination of coenzyme Q10 in human breast milk by high-performance liquid chromatography. Biomed Chromatogr. 2006 Dec;20(12):1336-43. Miles MV, Patterson BJ, Schapiro MB, Hickey FJ, Chalfonte-Evans M, Horn PS, Hotze SL. Coenzyme Q10 absorption and tolerance in children with Down syndrome: a dose-ranging trial. Pediatr Neurol. 2006 Jul;35(1):30-7. Miles L, Miles MV, Tang PH, Horn PS, Quinlan JG, Wong B, Wenisch A, Bove KE. Ubiquinol: a potential biomarker for tissue energy requirements and oxidative stress. Clin Chim Acta. 2005 Oct;360(1-2):87-96. Miles L, Miles MV, Tang PH, Horn PS, Wong BL, DeGrauw TJ, Morehart PJ, Bove KE. Muscle coenzyme Q: a potential test for mitochondrial activity and redox status. Pediatr Neurol. 2005 May;32(5):318-24.
|
Diego A. Morita, MD
Co-Director, New Onset Seizure Clinic
Academic Information
Assistant Professor, UC Department of Pediatrics
Show All
Specialties
Clinical InterestsEpilepsy; therapeutic drug management; pharmacogenetics Research InterestsClinical pharmacology; population pharmacokinetics; antiepileptic drug tolerability
Biography
Dr. Morita obtained his Medical Degree with honors from the University of Buenos Aires School of Medicine in Buenos Aires, Argentina. He finished a three-year residency in Pediatrics at Buenos Aires British Hospital in Buenos Aires, Argentina. In 1996, he came to the United States and continued his training in Pediatrics at Miami Children's Hospital in Miami, Florida. Dr. Morita was then a resident in Neurology at the University of Cincinnati, and later a fellow in Child Neurology at Cincinnati Children's. He completed fellowship training in Clinical Neurophysiology and Epilepsy, and Epilepsy Clinical Neuropharmacology, both at Cincinnati Children's. After his fellowships, Dr. Morita opened a Child Neurology private practice in Buenos Aires, Argentina, and in 2005 returned and joined the faculty at Cincinnati Children's. Dr. Morita's interests currently include the objective assessment of antiepileptic drug side effects, pharmacogenetics of antiepileptic drugs, and individualization of drug therapy.
Education and Training
MD: University of Buenos Aires, Buenos Aires, Argentina, 1992.
Residency: Buenos Aires British Hospital, Buenos Aires, Argentina; Miami Children's Hospital, Miami, FL; University of Cincinnati, Cincinnati, OH.
Fellowship: Child Neurology: Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Clinical Neurophysiology and Epilepsy: Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Epilepsy Clinical Neuropharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Publications
View PubMed Publications
Modi AC, Guilfoyle SM, Morita DA, Glauser TA. Development and reliability of a correction factor for parent-reported adherence to pediatric antiepileptic drug therapy. Epilepsia. 2011 Feb;52(2):370-6. doi: 10.1111/j.1528-1167.2010.02789.x. Holland KD, Monahan S, Morita D, Vartzelis G, Glauser TA. Valproate in children with newly diagnosed idiopathic generalized epilepsy. Acta Neurol Scand. 2010 Mar;121(3):149-53. Modi AC, King AS, Monahan SR, Koumoutsos JE, Morita DA, Glauser TA. Even a single seizure negatively impacts pediatric health-related quality of life. Epilepsia. 2009 Sep;50(9):2110-6. Modi AC, Morita DA, Glauser TA. One-month adherence in children with new-onset epilepsy: white-coat compliance does not occur. Pediatrics. 2008 Apr;121(4):e961-6.
|
Hope L. O'Brien, MD
Director, Young Adult Headache Program, Division of Neurology
is an adult neurologist, interested in the transition stages of chronic headache as one develops from childhood into adults, with focus on the unique aspects of headaches and its impact on late adolescents and young adults. This includes identifying modifiable features in children with migraine that will result in reduction of intractable cases as one develops.
513-636-4222
neurodesk@cchmc.org
Hope L. O'Brien, MD
Director, Young Adult Headache Program, Division of Neurology
Director, Headache Medicine Fellowship
Academic Information
Assistant Professor, UC Department of Pediatrics
|
Douglas F. Rose, MD
Pediatric Epileptologist
is interested in clinical neurophysiology of normal and abnormal brain function across multiple neuropsychiatric disorders using multiple modalities, principally electroencephalography (EEG), magnetoencephalography (MEG) and functional magnetic resonance imaging (fMRI). The normal brain function includes developmental vision, hearing, touch perception, spontaneous motor movement, attention, memory, language and pain perception. The neuropsychiatric disorders include epilepsy, cerebral palsy, stroke, tic disorders, obsessive-compulsive disorder and traumatic brain injury.
513-636-4222
douglas.rose@cchmc.org
Douglas F. Rose, MD
Pediatric Epileptologist
Academic Information
Professor, UC Department of Pediatrics
Show All
Specialties
Clinical InterestsEpilepsy; improvement of the quality of life for children with epilepsy; studies of brain and physiology to better understand brain function Research InterestsNeuropharmacology; epilepsy surgery; central auditory processing; magnetoencephalography; functional cortical mapping; fMRI; SPECT; vagus nerve stimulator; ketogenic diet; language development and language disorders
Biography
Dr. Rose grew up in Cleveland, Ohio. He and his wife lived briefly in Fairborn and Dayton, Ohio when first married. Subsequently they moved to Washington, DC to study and work at the National Institutes of Health. They then moved to Albuquerque, New Mexico for several years to continue work and research, before moving to Memphis, Tennessee and then Cincinnati.
Education and Training
MD: Case Western Reserve University, Cleveland, Ohio, 1977 Residency: Rainbow Babies and Childrens, Cleveland, Ohio, 1979 Fellowship: University Hospitals, Cleveland, Ohio, 1982 Instructor:, Department of Neurology, University Hospitals, Cleveland, Ohio, 1983 Fellowship: Epilepsy, National Institutes of Health, Bethesda, Md., 1983-1984 Fellowship: Neurophysiology, National Institutes of Health, Bethesda, Md., 1984-1985 Medical Staff Fellow: Clinical Epilepsy Section, National Institutes of Health, 1983-1984 Medical Staff Fellow: EEG Laboratory, National Institutes of Health, 1984-1986 Medical Staff Fellow: Unit on Neurophysiology, National Institutes of Health, 1986-1987 Senior Staff Fellow: Unit on Neurophysiology, National Institutes of Health, 1987-1989 Associate Professor: Department of Neurology, University of New Mexico, Albuquerque, N.M., 1989-1992 Director: Center for Magnetoencephalography, Albuquerque, N.M., 1989-1992 Associate Professor: Department of Pediatrics, University of Tennessee, Memphis, Tenn. 1992-2000 Associate Professor: Department of Neurology, University of Tennessee, Memphis, Tenn. 1992-2000 Adjunct Associate Professor: Memphis Speech and Hearing Center, Department of Audiology, University of Memphis, Tenn., 1998-present. Division Chief: Child Neurology, Department of Pediatrics, University of Tennessee, 1994-2000 Medical Director: Comprehensive Epilepsy Center, Le Bonheur Children's Medical, Center, Memphis, Tenn., 1992-2000 Director: Cincinnati Children's Neurodiagnostic Laboratory, 2003 to present. Director: Cincinnati Children's Clinical Neurophysiology Fellowship Program, 2001 to present. Medical Director: Cincinnati Children's MEG Center, 2005 to present. Certification: Pediatrics 1984 ; Neurology with special competence in Child Neurology 1984; Clinical Neurophysiology 1986; Added Qualifications in Clinical Neurophysiology 1994 Practice Locations: Cincinnati Children's Hospital Medical Center Main Campus; Outpatient Services -- Anderson
|
Mark Schapiro, MD
is interested in identifying specific biomarkers for future neurological deficits, which may also serve as therapeutic targets in neonatal care. For example, premature newborns are at high risk for later neurological disorders due to disruption of normal brain development by prematurity, in association with ischemic and inflammatory injury in utero or in the perinatal period.
513-636-4222
mark.schapiro@cchmc.org
Mark Schapiro, MD
Academic Information
Assistant Professor, UC Department of Pediatrics
Show All
Specialties
Genetic and hormonal determinants of brain function; aging of the nervous system in developmental disorders
Education and Training
MD: University of Tennessee, Memphis, Tenn. 1976. Residency: Pediatric Neurology, Boston City Hospital, Boston, Mass., 1980-1983. Fellowship: National Institute on Aging, 1983-1989. Certification: Pediatrics, 1985; Neurology and Psychiatry.
|
Matthew R. Skelton, PhD
is a neuroscientist who has a basic research program on the role of creatine in brain structure and function. The primary focus of his lab is the study of the mechanisms underlying intellectual disability caused by mutations in the creatine transporter gene.
matthew.skelton@cchmc.org
Matthew R. Skelton, PhD
Academic Information
Assistant Professor, UC Department of Pediatrics
Show All
Education and Training
BA: Biology, Bellamarine University, Louisville, KY, 2000. PhD: Molecular and Developmental Biology, University of Cincinnati, Cincinnati, OH, 2006.
Publications
View PubMed Publications
Vorhees CV, He E, Skelton MR, Graham DL, Schaefer TL, Grace CE, Braun AA, Amos-Kroohs R, Williams MT. Comparison of (+)-methamphetamine, ±-methylenedioxymethamphetamine, (+)-amphetamine and ±-fenfluramine in rats on egocentric learning in the Cincinnati water maze. Synapse. 2011 May;65(5):368-78.
Graham DL, Grace CE, Braun AA, Schaefer TL, Skelton MR, Tang PH, Vorhees CV, Williams MT. Effects of developmental stress and lead (Pb) on corticosterone after chronic and acute stress, brain monoamines, and blood Pb levels in rats. Int J Dev Neurosci. 2011 Feb;29(1):45-55. Skelton MR, Schaefer TL, Graham DL, Degrauw TJ, Clark JF, Williams MT, Vorhees CV. Creatine transporter (CrT; Slc6a8) knockout mice as a model of human CrT deficiency. PLoS One. 2011 Jan 13;6(1):e16187. Braun AA, Skelton MR, Vorhees CV, Williams MT. Comparison of the elevated plus and elevated zero mazes in treated and untreated male Sprague-Dawley rats: effects of anxiolytic and anxiogenic agents. Pharmacol Biochem Behav. 2011 Jan;97(3):406-15. Grace CE, Schaefer TL, Graham DL, Skelton MR, Williams MT, Vorhees CV. Effects of inhibiting neonatal methamphetamine-induced corticosterone release in rats by adrenal autotransplantation on later learning, memory, and plasma corticosterone levels. Int J Dev Neurosci. 2010 Jun;28(4):331-42.
Grace CE, Schaefer TL, Herring NR, Graham DL, Skelton MR, Gudelsky GA, Williams MT, Vorhees CV. Effect of a neurotoxic dose regimen of (+)-methamphetamine on behavior, plasma corticosterone, and brain monoamines in adult C57BL/6 mice. Neurotoxicol Teratol. 2010 May-Jun;32(3):346-55.
Sun Y, Liou B, Ran H, Skelton MR, Williams MT, Vorhees CV, Kitatani K, Hannun YA, Witte DP, Xu YH, Grabowski GA. Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits. Hum Mol Genet. 2010 Mar 15;19(6):1088-97.
Sun Y, Ran H, Zamzow M, Kitatani K, Skelton MR, Williams MT, Vorhees CV, Witte DP, Hannun YA, Grabowski GA. Specific saposin C deficiency: CNS impairment and acid beta-glucosidase effects in the mouse. Hum Mol Genet. 2010 Feb 15;19(4):634-47
Skelton MR, Schaefer TL, Herring NR, Grace CE, Vorhees CV, Williams MT. Comparison of the developmental effects of 5-methoxy-N,N-diisopropyltryptamine (Foxy) to (+/-)-3,4-methylenedioxymethamphetamine (ecstasy) in rats. Psychopharmacology (Berl). 2009 Jun;204(2):287-97. Vorhees CV, Skelton MR, Grace CE, Schaefer TL, Graham DL, Braun AA, Williams MT. Effects of (+)-methamphetamine on path integration and spatial learning, but not locomotor activity or acoustic startle, align with the stress hyporesponsive period in rats. Int J Dev Neurosci. 2009 May;27(3):289-98.
|
Shannon M. Standridge, MPH, DO
is interested in the specific field of pediatric neurology, focusing on cost effective analyses. She seeks to understand the significance of healthcare savings and the magnitude of improvement in quality of life over an expected lifetime in young children undergoing epilepsy surgery.
513-636-4222
neurodesk@cchmc.org
Shannon M. Standridge, MPH, DO
Academic Information
Assistant Professor, UC Department of Pediatrics
Show All
Specialties
Education and Training
Fellowship: Neurophysiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2008; Neurology, Nationwide Children's Hospital, Columbus, OH, 2007. Residency: Pediatrics, Nationwide Children's Hospital, Columbus, OH, 2004. MPH: The Ohio State University College of Public Health, Columbus, OH, 2008. DO: Kansas City University of Medicine and Biosciences, Kansas City, MO, 2002. BS: Biology, Lyon College, Batesville, AS, 1997.
Publications
View PubMed Publications
Standridge SM. Idiopathic intracranial hypertension in children: a review and algorithm. Pediatr Neurol. 2010 Dec;43(6):377-90.
Standridge SM, Holland KD, Horn PS. Cardiac arrhythmias and ictal events within an epilepsy monitoring unit. Pediatr Neurol. 2010 Mar;42(3):201-5.
Standridge SM, O'Brien SH. Idiopathic intracranial hypertension in a pediatric population: a retrospective analysis of the initial imaging evaluation. J Child Neurol. 2008 Nov;23(11):1308-11.
|
Mary Sutton, MD
Academic Information
Assistant Professor, UC Department of Pediatrics
Phone: 513-636-4222
Fax: 513-636-3980
Show All
Specialties
Education and Training
MD: University of Rochester School of Medicine and Dentistry, Rochester, NY, 1989. Residency: Pediatrics, Children's Hospital, Boston, MA. Fellowship: Neurology, Children's Hospital, Boston, MA. Certification: Pediatrics, 1996; Neurology, 1996.
|
Cameron Thomas, MD
Academic Information
Assistant Professor, UC Department of Pediatrics
Show All
Education and Training
MD: University of Colorado Health Sciences Center, Denver, CO, 2005. Residency: Child Neurology, Cincinnati Children’s Hospital, Cincinnati, OH. Certification: Neurology with Special Qualification in Child Neurology, 2010.
Publications
Thomas CW, Meinzen-Derr J, Hoath SB, Narendran V. Neurodevelopmental Outcomes of Extremely Low Birth Weight Infants Ventilated with Continuous Positive Airway Pressure vs. Mechanical Ventilation. Indian J Pediatr. 2011. Epub ahead of print.
|
Jennifer J. Vannest, PhD
is interested in the use of functional MRI and behavioral testing to examine how epilepsy and neurodevelopmental disorders affect language function and the brain circuitry that supports it. The goal of these studies is to provide better treatment and educational strategies for children with these disorders.
513-636-6959
jennifer.vannest@cchmc.org
Jennifer J. Vannest, PhD
Academic Information
Assistant Professor, UC Department of Pediatrics
Show All
Specialties
Clinical InterestsCognitive neuroscience of language and memory (using functional MRI); cognitive effects of epilepsy and neurodevelopmental disorders Research InterestsNeurological disorders and language impairments
Biography
Jennifer Vannest, PhD, completed her undergraduate education at the Ohio State University and continued there for her graduate work. Her PhD is in Linguistics, and in addition, her graduate training included a number of courses in Cognitive Psychology, Neuropsychology and Speech and Hearing Sciences. As a postdoctoral fellow at University of Michigan and University of Rochester, Dr. Vannest was trained to use functional MRI to study the brain mechanisms underlying language skill. Dr. Vannest came to Cincinnati Children's Hospital Medical Center in 2006, and her current research makes use of functional MRI to examine how epilepsy and neurodevelopmental disorders affect language function, ultimately leading to better treatment and educational strategies for children with these disorders.
Education and Training
PhD: Ohio State University, Linguistics. Postdoctoral Training: University of Michigan (Psychology), University of Rochester (Brain and Cognitive Sciences).
Publications
View PubMed Publications
Vannest J, Newport EL, Newman AJ, Bavelier D. Interplay between morphology and frequency in lexical access: The case of the base frequency effect. Brain Res. 2011 Feb 10;1373:144-59.
Korostenskaja M, Pardos M, Fujiwara H, Kujala T, Horn P, Rose D, Byars A, Brown D, Seo JH, Wang Y, Vannest J, Xiang J, Degrauw T, Näätänen R, Lee KH. Neuromagnetic evidence of impaired cortical auditory processing in pediatric intractable epilepsy. Epilepsy Res. 2010 Nov;92(1):63-73. Vannest J, Rasmussen J, Eaton KP, Patel K, Schmithorst V, Karunanayaka P, Plante E, Byars A, Holland S. FMRI activation in language areas correlates with verb generation performance in children. Neuropediatrics. 2010 Oct;41(5):235-9.
Szaflarski JP, Eaton K, Ball AL, Banks C, Vannest J, Allendorfer JB, Page S, Holland SK. Poststroke Aphasia Recovery Assessed With Functional Magnetic Resonance Imaging and a Picture Identification Task. J Stroke Cerebrovasc Dis. 2010 Aug 17.
Karunanayaka P, Schmithorst VJ, Vannest J, Szaflarski JP, Plante E, Holland SK. A group independent component analysis of covert verb generation in children: a functional magnetic resonance imaging study. NeuroImage. 2010 May 15;51(1):472-87.
Vannest J, Karunanayaka PR, Schmithorst VJ, Szaflarski JP, Holland SK. Language networks in children: evidence from functional MRI studies. AJR Am J Roentgenol. 2009 May;192(5):1190-6.
Vannest JJ, Karunanayaka PR, Altaye M, Schmithorst VJ, Plante EM, Eaton KJ, Rasmussen JM, Holland SK. Comparison of fMRI data from passive listening and active-response story processing tasks in children. J Magn Reson Imaging. 2009 Apr;29(4):971-6.
Wang Y, Xiang J, Kotecha R, Vannest J, Liu Y, Rose D, Schapiro M, Degrauw T. Spatial and frequency differences of neuromagnetic activities between the perception of open- and closed-class words. Brain Topogr. 2008 Dec;21(2):75-85. Liu Y, Xiang J, Wang Y, Vannest JJ, Byars AW, Rose DF. Spatial and frequency differences of neuromagnetic activities in processing concrete and abstract words. Brain Topogr. 2008 Spring;20(3):123-9. Vannest J, Szaflarski JP, Privitera MD, Schefft BK, Holland SK. Medial temporal fMRI activation reflects memory lateralization and memory performance in patients with epilepsy. Epilepsy Behav. 2008 Apr;12(3):410-8.
|
Charles V. Vorhees, PhD
focuses on how drugs, genes, immune activators and environmental agents adversely affect the developing brain, along with Dr. Michael Williams. Projects range from early stress to prenatal exposure to drugs of abuse, from creatine transporter deficiency to genes associated with depression, and from lead-manganese toxicity to autism. The overarching interest is on developmental origins of nervous system disorders, particularly those originating prenatally using behavioral, neurochemical, immunohistochemical, pharmacological and genetic methods. Visit the Vorhees/Williams Lab.
513-636-8622
charles.vorhees@cchmc.org
Charles V. Vorhees, PhD
Academic Information
Professor, UC Department of Pediatrics
Show All
Specialties
Effects of amphetamines on brain development, behavior, and neurotoxicity; neurobiological substrates of learning and memory; proteins for neurotransmitter receptors, second messenger transduction, and regulators of signaling pathways. Visit the Vorhees-Williams-Skelton Lab.
Biography
Charles Vorhees, PhD, has served on numerous National Institutes of Health site visit committees, special emphasis panels, and ad hoc review committees since 1984. He was a member of a study section from 1994-1998, and served as interim chair in 1997. Dr. Vorheeshas also reviewed grant applications for the National Science Foundation, Veterans Administration, Wellcome Trust, March of Dimes, and other agencies. He has served on advisory committees to the US Food and Drug Administration, US Environmental Protection agency, National Research Council, several private foundations, and a number of pharmaceutical companies. Dr. Vorhees was Director of the Graduate Program in Molecular and Developmental Biology at the University of Cincinnati College of Medicine from 1998-2004. Visit the Vorhees Lab Site Visit the Animal Behavioral Core Site
Education and Training
MA: Neurobiology Program, Vanderbilt University, Nashville, TN, 1973. PhD: Neurobiology Program, Vanderbilt University, Nashville, TN, 1976.
Publications
View PubMed Publications
Graham DL, Grace CE, Braun AA, Schaefer TL, Skelton MR, Tang PH, Vorhees CV, Williams MT. Effects of developmental stress and lead (Pb) on corticosterone after chronic and acute stress, brain monoamines, and blood Pb levels in rats. Int J Dev Neurosci. 2011 Feb;29(1):45-55.
Skelton MR, Schaefer TL, Graham DL, Degrauw TJ, Clark JF, Williams MT, Vorhees CV. Creatine transporter (CrT; Slc6a8) knockout mice as a model of human CrT deficiency. PLoS One. 2011 Jan 13;6(1):e16187.
Curran CP, Vorhees CV, Williams MT, Genter MB, Miller ML, Nebert DW. In utero and lactational exposure to a complex mixture of polychlorinated biphenyls: toxicity in pups dependent on the Cyp1a2 and Ahr genotypes. Toxicol Sci. 2011 Jan;119(1):189-208.
Braun AA, Skelton MR, Vorhees CV, Williams MT. Comparison of the elevated plus and elevated zero mazes in treated and untreated male Sprague-Dawley rats: effects of anxiolytic and anxiogenic agents. Pharmacol Biochem Behav. 2011 Jan;97(3):406-15. Schaefer TL, Grace CE, Gudelsky GA, Vorhees CV, Williams MT. Effects on plasma corticosterone levels and brain serotonin from interference with methamphetamine-induced corticosterone release in neonatal rats. Stress. 2010 Nov;13(6):469-80.
Schaefer TL, Lingrel JB, Moseley AE, Vorhees CV, Williams MT. Targeted mutations in the Na,K-ATPase alpha 2 isoform confer ouabain resistance and result in abnormal behavior in mice. Synapse. 2010 Oct 8. Herring NR, Gudelsky GA, Vorhees CV, Williams MT. (+)-Methamphetamine-induced monoamine reductions and impaired egocentric learning in adrenalectomized rats is independent of hyperthermia. Synapse. 2010 Oct;64(10):773-85. Zhu H, Mingler MK, McBride ML, Murphy AJ, Valenzuela DM, Yancopoulos GD, Williams MT, Vorhees CV, Rothenberg ME. Abnormal response to stress and impaired NPS-induced hyperlocomotion, anxiolytic effect and corticosterone increase in mice lacking NPSR1. Psychoneuroendocrinology. 2010 Sep;35(8):1119-32. Vorhees CV, He E, Skelton MR, Graham DL, Schaefer TL, Grace CE, Braun AA, Amos-Kroohs R, Williams MT. Comparison of (+)-methamphetamine, ±-Methylenedioxymethamphetamine, (+)-amphetamine and ±-fenfluramine in rats on egocentric learning in the Cincinnati water maze. Synapse. 2010 Aug 20.
Grace CE, Schaefer TL, Graham DL, Skelton MR, Williams MT, Vorhees CV. Effects of inhibiting neonatal methamphetamine-induced corticosterone release in rats by adrenal autotransplantation on later learning, memory, and plasma corticosterone levels. Int J Dev Neurosci. 2010 Jun;28(4):331-42.
Grants
Effects of Lead, Manganese and Stress During Development. Co-investigator. National Institutes of Health. 2006 - 2011. Effects of Neonatal MDMA on Brain and Behavior. Principal Investigator. National Institutes of Health. 2006 - 2011. Training Grant in Teratology. Principal Investigator. National Institutes of Health. 2007 - 2012.
|
Anna Weber Byars, PhD, ABPP-Cn
Pediatric Neuropsychologist
is focused on neuropsychological and behavioral aspects of epilepsy. She also collaborates with researchers in the Imaging Research Center on studies of cognitive development as well as clinicians conducting clinical trials in genetic diseases.
513-636-4222
Anna Weber Byars, PhD, ABPP-Cn
Pediatric Neuropsychologist
Academic Information
Associate Professor, UC Department of Pediatrics
Phone: 513-636-4222
Fax: 513-636-3980
Show All
Specialties
Functional MRI; stroke; epilepsy; language disorders
Education and Training
PhD: University of Alabama at Birmingham, Birmingham, AL. Internship: West Virginia University School of Medicine, Morgantown, WV. Fellowship: Pediatric Neuropsychology, Children's Hospital Medical Center, Cincinnati, OH.
|
Kris R. Wesselkamper, MD
Pediatric Neurologist
Academic Information
Assistant Professor, UC Department of Pediatrics
Show All
Education and Training
MD: University of Cincinnati, Cincinnati, OH, 2000. Pediatric Residency: MetroHealth Medical Center, Cleveland, OH, 2000-2003. Child Neurology Residency: Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2003-2006. Board Certification: Neurology with Special Qualification in Child Neurology, American Board of Psychiatry and Neurology, 2007.
|
Michael T. Williams, PhD
focuses on how drugs, genes, immune activators and environmental agents adversely affect the developing brain, along with Dr. Charles Vorhees. Projects range from early stress to prenatal exposure to drugs of abuse, from creatine transporter deficiency to genes associated with depression, and from lead-manganese toxicity to autism. The overarching interest is on developmental origins of nervous system disorders, particularly those originating prenatally using behavioral, neurochemical, immunohistochemical, pharmacological and genetic methods. Visit the Vorhees/Williams/Skelton Lab.
513-636-4222
michael.williams@cchmc.org
Michael T. Williams, PhD
Academic Information
Associate Professor, UC Department of Pediatrics
Show All
Specialties
Education and Training
AA: Psychology, Belleville Area College.
BS: Psychology, Wright State University.
PhD: Biomedical Sciences, Wright State University.
Postdoctoral Fellow: Psychoneuroimmunology, Ohio State University.
Postdoctoral Fellow: Teratology, Children's Hospital Research Foundation.
Publications
View PubMed Publications
Skelton MR, Schaefer TL, Graham DL, Degrauw TJ, Clark JF, Williams MT, Vorhees CV. Creatine Transporter (CrT; Slc6a8) Knockout Mice as a Model of Human CrT Deficiency. PLoS One. 2011 Jan 13;6(1):e16187.
Curran CP, Vorhees CV, Williams MT, Genter MB, Miller ML, Nebert DW. In utero and lactational exposure to a complex mixture of polychlorinated biphenyls: toxicity in pups dependent on the Cyp1a2 and Ahr genotypes. Toxicol Sci. 2011 Jan;119(1):189-208.
Graham DL, Grace CE, Braun AA, Schaefer TL, Skelton MR, Tang PH, Vorhees CV, Williams MT. Effects of developmental stress and lead (Pb) on corticosterone after chronic and acute stress, brain monoamines, and blood Pb levels in rats. Int J Dev Neurosci. 2011 Feb;29(1):45-55.
Braun AA, Skelton MR, Vorhees CV, Williams MT. Comparison of the elevated plus and elevated zero mazes in treated and untreated male Sprague-Dawley rats: effects of anxiolytic and anxiogenic agents. Pharmacol Biochem Behav. 2011 Jan;97(3):406-15. Schaefer TL, Grace CE, Gudelsky GA, Vorhees CV, Williams MT. Effects on plasma corticosterone levels and brain serotonin from interference with methamphetamine-induced corticosterone release in neonatal rats. Stress. 2010 Nov;13(6):469-80.
Herring NR, Gudelsky GA, Vorhees CV, Williams MT.(+)-Methamphetamine-induced monoamine reductions and impaired egocentric learning in adrenalectomized rats is independent of hyperthermia. Synapse. 2010 Oct;64(10):773-85. Schaefer TL, Lingrel JB, Moseley AE, Vorhees CV, Williams MT. Targeted mutations in the Na,K-ATPase alpha 2 isoform confer ouabain resistance and result in abnormal behavior in mice. Synapse. 2010 Oct 8. Vorhees CV, He E, Skelton MR, Graham DL, Schaefer TL, Grace CE, Braun AA, Amos-Kroohs R, Williams MT. Comparison of (+)-methamphetamine, ±-Methylenedioxymethamphetamine, (+)-amphetamine and ±-fenfluramine in rats on egocentric learning in the Cincinnati water maze. Synapse. 2010 Aug 20. Grace CE, Schaefer TL, Graham DL, Skelton MR, Williams MT, Vorhees CV. Effects of inhibiting neonatal methamphetamine-induced corticosterone release in rats by adrenal autotransplantation on later learning, memory, and plasma corticosterone levels. Int J Dev Neurosci. 2010 Jun;28(4):331-42.
Zhu H, Mingler MK, McBride ML, Murphy AJ, Valenzuela DM, Yancopoulos GD, Williams MT, Vorhees CV, Rothenberg ME. Abnormal response to stress and impaired NPS-induced hyperlocomotion, anxiolytic effect and corticosterone increase in mice lacking NPSR1. Psychoneuroendocrinology. 2010 Sep;35(8):1119-32.
|
Brenda Wong, MD, MBBS
Professor of Clinical Pediatrics and Neurology, Director of Comprehensive Neuromuscular Center
focuses on neuromuscular disorders in children including clinical research in Duchenne muscular dystrophy and spinal muscular atrophy and genomics in DMD and NM disorders.
513-636-4222
brenda.wong@cchmc.org
Brenda Wong, MD, MBBS
Professor of Clinical Pediatrics and Neurology, Director of Comprehensive Neuromuscular Center
Academic Information
Associate Professor, UC Department of Pediatrics
Show All
Specialties
Biography
After medical school, Brenda Wong, MD, received training in General Pediatrics and worked as a pediatrician for a few years before doing her three-year Child Neurology fellowship at Children's Hospital Medical Center, Cincinnati. Dr. Wong also received training in Pediatric Neuromuscular Disorders at Hammersmith Hospital, London with Dr. Victor Dubowitz and Dr. Francesco Muntoni. Dr. Wong's training in EMGs was accomplished with Dr. John Quinlan at Department of Neurology, University of Cincinnati. Post fellowship training, Dr. Wong was practicing child neurology in private practice prior to joining Children's Hospital Medical Center of Cincinnati in 1999. Besides general neurology patients, Dr. Wong sees patients with neuromuscular disorders in the Neuromuscular Clinic and provide diagnostic services like EMGs and evaluation for muscle biopsies. Comprehensive management is supported by the Department of Rehabilitative Medicine, Pulmonary Medicine, Pediatric Orthopedics and the Muscular Dystrophy Association.
Education and Training
MD: University of Singapore, 1980. Residency: University Department of Pediatrics, Singapore, 1981, 1984-85, Royal Hospital for Sick Children, Edinburgh 1985-88. Fellowship: Child Neurology, Children's Hospital Medical Center, Cincinnati, OH, 1994-97; Neuromuscular Disorders, Hammersmith Hospital, London, 1997. Certification: Child Neurology, 1998.
Publications
View PubMed Publications
Miles MV, Putnam PE, Miles L, Tang PH, DeGrauw AJ, Wong BL, Horn PS, Foote HL, Rothenberg ME. Acquired coenzyme Q10 deficiency in children with recurrent food intolerance and allergies. Mitochondrion. 2011 Jan;11(1):127-35. Kim HK, Laor T, Horn PS, Racadio JM, Wong B, Dardzinski BJ. T2 mapping in Duchenne muscular dystrophy: distribution of disease activity and correlation with clinical assessments. Radiology. 2010 Jun;255(3):899-908.
Kim HK, Laor T, Horn PS, Wong B. Quantitative assessment of the T2 relaxation time of the gluteus muscles in children with Duchenne muscular dystrophy: a comparative study before and after steroid treatment. Korean J Radiol. 2010 May-Jun;11(3):304-11.
Yang Z, Funke BH, Cripe LH, Vick GW 3rd, Mancini-Dinardo D, Peña LS, Kanter RJ, Wong B, Westerfield BH, Varela JJ, Fan Y, Towbin JA, Vatta M. LAMP2 microdeletions in patients with Danon disease. Circ Cardiovasc Genet. 2010 Apr;3(2):129-37.
Henderson RC, Berglund LM, May R, Zemel BS, Grossberg RI, Johnson J, Plotkin H, Stevenson RD, Szalay E, Wong B, Kecskemethy HH, Harcke HT. The relationship between fractures and DXA measures of BMD in the distal femur of children and adolescents with cerebral palsy or muscular dystrophy. J Bone Miner Res. 2010 Mar; 25(3):520-6.
Grants
|
Steve W. Wu, MD
is interested in pediatric movement disorders, including Tourette syndrome. He is also actively involved in transcranial magnetic stimulation research. Visit the Gilbert/Wu Lab.
513-636-4222
Steve W. Wu, MD
Academic Information
Assistant Professor, UC Department of Pediatrics
Show All
Specialties
Neuroplasticity; movement disorders; transcranial magnetic stimulation; transcranial magnetic stimulation lab Visit the Gilbert-Wu Lab.
Biography
Dr. Steve Wu is a pediatric neurologist with interests in children with movement disorders. His research interest focuses on movement disorders and neuroplasticity of the brain. Dr. Wu collaborates with Dr. Donald Gilbert in the Transcranial Magnetic Stimulation Lab at Cincinnati Children’s Hospital Medical Center.
Education and Training
BA: University of California, Berkeley CA, 1997.
MD: Vanderbilt University, Nashville TN, 2003.
Residency: Pediatrics and Pediatric Neurology, Cincinnati Children’s Hospital Medical Center, Cincinnati OH, 2003-2008.
Fellowship: Pediatric Movement Disorders, Cincinnati Children’s Hospital Medical Center, Cincinnnati OH, 2008-2009.
Publications
Lehman LL, Gilbert DL, Leach JL, Wu SW, Standridge SM. Vertebral Artery Dissection Leading to Stroke Caused by Violent Neck Tics of Tourette Syndrome. Neurology. 2011. Wu SW, Gilbert DL. Altered neurophysiologic response to intermittent theta burst stimulation in Tourette Syndrome. Brain Stimulation. 2011. Szaflarski J, Vannest J, Wu SW, DiFrancesco M, Banks C, Gilbert DL. Excitatory repetitive transcranial magnetic stimulation induces improvements in chronic post-stroke aphasia. Med Sci Monit. 2011 Feb;17(3):132-139. Wu SW, Harris E, Gilbert DL. Tic suppression: the medical model. J Child Adolesc Psychopharmacol. 2010 Aug;20(4):263-276. Harris E, Wu SW. Children with tic disorders: How to match treatment with symptoms. Current Psychiatry. 2010;9:29-36. Wu SW, Graham B, Gelfand MJ, Gruppo RE, Dinopolous A, Gilbert DL. Clinical and positron emission tomography findings of chorea associated with primary antiphospholipid antibody syndrome. Mov Disord. 2007 Sep;22(12):1813-1815. Wu SW, Gilbert DL, Phillips T. Retrospective analysis of electroencephalograms in neonates suspected of having seizures. J Child Neurol. 2007;22:669-670.
|
Jing Xiang, MD, PhD
Director of MEG Research
focuses on the identification of pathological HFBS in epilepsy, migraine and other brain disorders. Dr. Xiang is currently building on recent discoveries that the brain generates high-frequency brain signals (HFBS, ~2,632 Hz) and that magnetoencephalography (MEG) can detect HFBS noninvasively. Visit the Xiang Lab.
513-636-4222
jing.xiang@cchmc.org
Jing Xiang, MD, PhD
Director of MEG Research
Academic Information
Associate Professor, UC Department of Pediatrics
Show All
Specialties
Education and Training
MD: Postgraduate Medical School, Beijing, China, 1994. PhD: The Graduate University for Advanced Studies, Okazaki, Japan, 1998.
Publications
View PubMed Publications
Zhang F, Hammer T, Banks HL, Benson C, Xiang J, Fu QJ. Mismatch negativity and adaptation measures of the late auditory evoked potential in cochlear implant users. Hear Res. 2010 Dec 1.
Korostenskaja M, Pardos M, Fujiwara H, Kujala T, Horn P, Rose D, Byars A, Brown D, Seo JH, Wang Y, Vannest J, Xiang J, Degrauw T, Näätänen R, Lee KH. Neuromagnetic evidence of impaired cortical auditory processing in pediatric intractable epilepsy. Epilepsy Res. 2010 Nov;92(1):63-73.
Meng L, Xiang J, Kotecha R, Rose D, Zhao H, Zhao D, Yang J, Degrauw T. White matter abnormalities in children and adolescents with temporal lobe epilepsy. Magn Reson Imaging. 2010 Nov;28(9):1290-8.
Huo X, Wang Y, Kotecha R, Kirtman EG, Fujiwara H, Hemasilpin N, Degrauw T, Rose DF, Xiang J. High Gamma Oscillations of Sensorimotor Cortex During Unilateral Movement in the Developing Brain: a MEG Study. Brain Topogr. 2011 Jan;23(4):375-84.
Wang X, Xiang J, Wang Y, Pardos M, Meng L, Huo X, Korostenskaja M, Powers SW, Kabbouche MA, Hershey AD. Identification of abnormal neuromagnetic signatures in the motor cortex of adolescent migraine. Headache. 2010 Jun;50(6):1005-16.
Chen Y, Xiang J, Kirtman EG, Wang Y, Kotecha R, Liu Y. Neuromagnetic biomarkers of visuocortical development in healthy children. Clin Neurophysiol. 2010 Sep;121(9):1555-62.
Xiang J, Wang Y, Chen Y, Liu Y, Kotecha R, Huo X, Rose DF, Fujiwara H, Hemasilpin N, Lee K, Mangano FT, Jones B, DeGrauw T. Noninvasive localization of epileptogenic zones with ictal high-frequency neuromagnetic signals. J Neurosurg Pediatr. 2010 Jan;5(1):113-22.
Huo X, Xiang J, Wang Y, Kirtman EG, Kotecha R, Fujiwara H, Hemasilpin N, Rose DF, Degrauw T. Gamma oscillations in the primary motor cortex studied with MEG. Brain Dev. 2010 Sep;32(8):619-24.
Xiang J, Liu Y, Wang Y, Kirtman EG, Kotecha R, Chen Y, Huo X, Fujiwara H, Hemasilpin N, Lee K, Mangano FT, Leach J, Jones B, DeGrauw T, Rose D. Frequency and spatial characteristics of high-frequency neuromagnetic signals in childhood epilepsy. Epileptic Disord. 2009 Jun;11(2):113-25.
Xiang J, Liu Y, Wang Y, Kotecha R, Kirtman EG, Chen Y, Huo X, Fujiwara H, Hemasilpin N, DeGrauw T, Rose D. Neuromagnetic correlates of developmental changes in endogenous high-frequency brain oscillations in children: a wavelet-based beamformer study. Brain Res. 2009 Jun 5;1274:28-39.
|
